In yesterday’s Wall Street session, Alzamend Neuro Inc. (NASDAQ:ALZN) shares traded at $0.53, down -11.31% from the previous session.
As of this writing, 1 analysts cover Alzamend Neuro Inc. (NASDAQ:ALZN). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $7.00 and a low of $7.00, we find $7.00. Given the previous closing price of $0.60, this indicates a potential upside of 1066.67 percent. ALZN stock price is now -50.08% away from the 50-day moving average and -48.73% away from the 200-day moving average. The market capitalization of the company currently stands at $52.67M.
There are 0 analysts who have given it a hold rating, whereas 1 have given it a buy rating. Brokers who have rated the stock have averaged $7.00 as their price target over the next twelve months.
With the price target of $8, Ascendiant Capital Markets recently initiated with Buy rating for Alzamend Neuro Inc. (NASDAQ: ALZN).
In other news, AULT MILTON C III, 10% Owner bought 5,000 shares of the company’s stock on Dec 21. The stock was bought for $4,049 at an average price of $0.81. Upon completion of the transaction, the 10% Owner now directly owns 11,046,001 shares in the company, valued at $5.85 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 19, 10% Owner AULT MILTON C III bought 23,000 shares of the business’s stock. A total of $18,813 was incurred on buying the stock at an average price of $0.82. This leaves the insider owning 11,041,001 shares of the company worth $5.85 million. Insiders disposed of 102,016 shares of company stock worth roughly $54068.48 over the past 1 year. A total of 2.60% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ALZN stock. A new stake in Alzamend Neuro Inc. shares was purchased by BLACKROCK INC. during the first quarter worth $316,000. NORTHERN TRUST CORP invested $23,000 in shares of ALZN during the first quarter. In the first quarter, DARK FOREST CAPITAL MANAGEMENT LP acquired a new stake in Alzamend Neuro Inc. valued at approximately $6,000. BENJAMIN EDWARDS INC acquired a new stake in ALZN for approximately $1,000. In total, there are 23 active investors with 8.20% ownership of the company’s stock.
Wednesday morning saw Alzamend Neuro Inc. (NASDAQ: ALZN) opened at $0.6150. During the past 12 months, Alzamend Neuro Inc. has had a low of $0.58 and a high of $2.44. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 6.30, and a quick ratio of 6.30. The fifty day moving average price for ALZN is $1.0617 and a two-hundred day moving average price translates $1.0337 for the stock.
The latest earnings results from Alzamend Neuro Inc. (NASDAQ: ALZN) was released for Jul, 2022. According to the Biotechnology Company, earnings per share came in at -$0.03, beating analysts’ expectations of -$0.07 by 0.04. This compares to -$0.04 EPS in the same period last year. The company reported revenue of $3.11 million for the quarter, compared to $3.58 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -13.34 percent.
Alzamend Neuro Inc.(ALZN) Company Profile
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company’s pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer’s, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient’s immunological system to combat Alzheimer’s disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.